MarketCapExport financials
Genmab A/S (GMAB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Genmab A/S Income Statement 2025-2011 | GMAB
Brief overview of financial results at Genmab A/S
The comparison covers a five-year financial horizon. According to figures from Genmab A/S, revenue changed from 1.1 billion DKK to 10.1 billion DKK over five years. The cumulative result was +792.4%, corresponding to roughly 54.9% per year. Sales grew at a rate typical of a strong expansion phase.
EBITDA was 762 million DKK at the beginning and 6.6 billion DKK at the end of the period (+762.2%). EBITDA underperformed the top-line trend. EBITDA margin was 67.3% at the start and 65% at the end. Cost pressure reduced operating profitability.
Net income changed from 764 million DKK to 4.8 billion DKK (+523.2%). The final year delivered the highest net income in the period.
Market capitalization changed from 7.3 billion DKK to 25 billion DKK (+241.8%). The financial trend was stronger than the market valuation.
Summary assessment
The five-year picture requires weighing both strengths and weaknesses. The financial profile benefits from a larger revenue base and a stronger final result. The most visible risks are weaker operating efficiency. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Genmab A/S
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.41 B | 1.91 B | 2.6 B | - | 25 B | 14.6 B | 9.09 B | 11.2 B | 11.4 B | 7.31 B | 3.76 B | 2.01 B | 645 M | - |
Shares |
64.7 M | 66.1 M | 66 M | - | 630 M | 630 M | 613 M | 608 M | 599 M | 585 M | 563 M | 510 M | 460 M | - |
Historical Prices |
21.8 | 28.8 | 39.3 | 33.5 | 33.9 | 22.8 | 17.3 | 20.8 | 19.8 | 12.3 | 7.4 | 4.45 | 1.83 | 0.654 |
Net Income |
- | 7.84 B | 4.35 B | - | 4.76 B | 2.17 B | 1.47 B | 1.1 B | 1.19 B | 764 M | 301 M | 112 M | -487 M | -596 M |
Revenue |
- | - | - | - | 10.1 B | 5.37 B | 3.03 B | 2.37 B | 1.82 B | 1.13 B | 850 M | 664 M | 485 M | 351 M |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | -182 M |
Operating Income |
- | - | - | - | - | 2.64 B | 1.38 B | 1.34 B | - | - | - | - | - | - |
EBITDA |
- | - | - | - | 6.57 B | 2.78 B | 1.47 B | 1.41 B | 1.09 B | 762 M | 278 M | 80.9 M | -102 M | -234 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | 67.9 M |
General and Administrative Expenses |
- | - | - | - | 661 M | 342 M | 214 M | 147 M | 102 M | 91.2 M | 79.5 M | 66.7 M | 64.6 M | 67.9 M |
Annual performance
Select metrics to display
All numbers in DKK currency
Quarterly Income Statement Genmab A/S
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.7 M | - | 66.1 M | - | 66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | 1.41 B | 7.84 B | 1.41 B | 4.35 B | 1.36 B | - | - | 1.89 B | - | - | - | 306 M | - | - | - | 3.38 B | - | - | - | 85 M | - | - | - | 261 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | 21.5 B | 5.4 B | 16.5 B | 4.2 B | - | - | 3.16 B | - | - | - | 1.97 B | - | - | - | 5.45 B | - | - | - | 774 M | - | - | - | 510 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | 985 M | 190 M | 226 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 20.5 B | 5.21 B | 16.2 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | 6.7 B | 1.64 B | 5.32 B | 1.5 B | - | - | 1.25 B | - | - | - | 787 M | - | - | - | 4.5 B | - | - | - | 137 M | - | - | - | 135 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | 6.7 B | 1.64 B | 5.32 B | 1.5 B | - | - | 1.25 B | - | - | - | 787 M | - | - | - | 4.5 B | - | - | - | 137 M | - | - | - | 135 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | 14.8 B | 3.76 B | 11.2 B | 2.7 B | - | - | 1.92 B | - | - | - | 1.18 B | - | - | - | 954 M | - | - | - | 637 M | - | - | - | 375 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | 3.79 B | 894 M | 3.3 B | 848 M | - | - | 633 M | - | - | - | 264 M | - | - | - | 179 M | - | - | - | 73 M | - | - | - | 55.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in DKK currency
The income statement is one of the three key financial reports of a company Genmab A/S (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Irlanda
Israel
Britain
Schweiz
Canada
